Ciliated muconodular papillary tumor/bronchiolar adenoma of the lung

Kao, Tzu-Hang; Yeh, Yi‐Chen

doi:10.1053/j.semdp.2021.04.002

Cited by 12 publications

(5 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[176][177][178] The lesions are typically small, most often measuring 0.5 to 1.5 cm. 184 Patients are middle-aged to elderly, with a median age of 72 years, without a sex predilection. 184 All patients with BA/CMPT reported to date have remained free of disease after surgical resection.…”

Section: Clinical Featuresmentioning

confidence: 99%

The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015

Nicholson

Tsao

Beasley

et al. 2022

Journal of Thoracic Oncology

656

480

View full text Add to dashboard Cite

Section: Clinical Featuresmentioning

confidence: 99%

The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015

Nicholson

Tsao

Beasley

et al. 2022

Journal of Thoracic Oncology

656

480

View full text Add to dashboard Cite

“…Five patients obtained PET/CT scans; 2 had minimal FDG uptake and 3 had no uptake. During imaging follow-up, the majority of cases grew gradually or slowly, with an average yearly growth rate of 0.49 mm/year, [ 5 ] and were easily misinterpreted as malignant lung lesions for surgical treatment.…”

Section: Discussionmentioning

confidence: 99%

Bronchiole adenoma/pulmonary ciliated mucinous nodular papillary tumor: Case series and literature review

Liu,

Cai,

Pan

et al. 2023

Medicine

View full text Add to dashboard Cite

Objective: To analyze the clinical-pathological characteristics of 3 cases of bronchiolar adenoma/pulmonary ciliary mucinous nodular papillary tumors, and to improve the understanding of bronchiolar adenoma (BA)/ciliated muconodular papillary tumors (CMPT) (bronchiolar adenoma/ciliated muconodular papillary tumor). Methods: Retrospective analysis was done on the clinical information, diagnosis, and treatment of 3 instances of BA/CMPT at the Second People’s Hospital of Weifang City. By scanning the CNKI, Wanfang, VIP database, and Pubmed database using the English key words “bronchiolar adenoma, ciliated muconodular papillary tumor,” respectively patients with comprehensive clinical data were gathered, and studies from January 2002 to August 2021 that were relevant to the patients were examined. Results: A total of 35 articles and 71 instances were found, including 3 cases in our hospital, for a total of 74 cases. There were 31 males and 43 females among them, ranging in age from 18 to 84 years (average 63 years), and 15 cases had a smoking history. The majority of them were discovered by physical examination and had no clinical symptoms. The majority of the imaging revealed solid nodules with variable forms, with some ground-glass nodules displaying vacuole and bronchial inflation signs. BA/CMPT are generally gray-white, gray-brown solid nodules with obvious boundaries but no envelope with a maximum dimension of 4 to 45 mm (average 10.6 mm) on gross examination. Acinar, papillary, and lepidic formations can be seen under the microscope at high magnification; the majority of these structures are made up of tripartite epithelial components, including basal cells, mucous cells, ciliated columnar cells, and alveolar epithelial cells, demonstrating a variety of combinations. An important basis for diagnosis in immunohistochemistry is the continuous positive basal cell layer that is shown by p63, p40, and CK5/6. BRAF and epidermal growth factor receptor are the genes that are most frequently mutated. All of the patients showed no signs of metastasis or recurrence during follow-up period. Conclusion: BA/CMPT is a rare benign tumor of lung epithelium. Because imaging and intraoperative cryosection diagnosis are easy to be misdiagnosed as malignant, it is necessary to further improve understanding and improve immunohistochemistry and genetic examination.

show abstract

“…However, it was negative in SP that showed positive SOX10 staining, because of its bronchial gland intercalated duct origin. 7,25 BRAF::V600E mutation and BRAF V600E immunohistochemistry are the most common genetic alterations in SP, GP/MP and BA/CMPT. The reported prevalence of BRAF::V600E mutations in SP, GP/MP and BA/CMPT was 44.4, 57.1 and 38.0-53.8%, respectively.…”

Section: Diagnostic Issues and Differential Diagnosismentioning

confidence: 99%

“…TTF‐1 was positive in BA/CMPT, which is probably due to its bronchiolar epithelium origin. However, it was negative in SP that showed positive SOX10 staining, because of its bronchial gland intercalated duct origin 7,25 …”

Section: Diagnostic Issues and Differential Diagnosismentioning

confidence: 99%

Pulmonary sialadenoma papilliferum and its mimics: what you need to know

Gao

Sun

2022

Histopathology

View full text Add to dashboard Cite

Pumonary salivary gland‐type tumours (SGT) represent a small but distinct group of primary lung neoplasms. These types of tumours originate from the submucosal bronchial glands of the tracheobronchial tree. Pulmonary SGTs differ greatly in the incidence of individual tumours from salivary gland tumours of the head and neck. Additionally, the vast majority of pulmonary SGT are malignant. Recently, pathological diagnosis has significantly improved with the application of molecular diagnostic technologies. However, the current knowledge of benign SGTs is limited; moreover, tumour diversity and overlapping morphological features of SGT represent diagnostic challenges such as correct tumour categorisation and their accurate differentiation from malignant lesions. Compounding this inherent difficulty has been the recent introduction of new variants, including sialadenoma papilliferum (SP). Pulmonary SP is very rare, with limited reports available, and most of the initial diagnoses rendered so far were incorrect, resulting in inappropriate treatment. Several cases of SP have recently been reported. This review will serve to update practicing pathologists on the morphology, immunophenotype and molecular characteristics of SP and its mimics.

show abstract

Ciliated muconodular papillary tumor/bronchiolar adenoma of the lung

Cited by 12 publications

References 32 publications

The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015

The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015

Bronchiole adenoma/pulmonary ciliated mucinous nodular papillary tumor: Case series and literature review

Pulmonary sialadenoma papilliferum and its mimics: what you need to know

Contact Info

Product

Resources

About